COVID-19: Updated Data and its Relation to the Cardiovascular System

Detalhes bibliográficos
Autor(a) principal: Ferrari, Filipe
Data de Publicação: 2020
Tipo de documento: preprint
Idioma: eng
Título da fonte: SciELO Preprints
Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/426
Resumo: In December 2019, a new human coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) or coronavirus disease 2019 (COVID‑19) by the World Health Organization, emerged in the city of Wuhan, China. Spreading globally, it is now considered pandemic, with approximately 3 million cases worldwide at the end of April. Its symptoms include fever, cough, and headache, but the main one is shortness of breath. In turn, it is believed that there is a relationship between COVID‑19 and damage to the heart muscle, and hypertensive and diabetic patients, for example, seem to have worse prognosis. Therefore, COVID‑19 may worsen in individuals with underlying adverse conditions, and a not negligible number of patients hospitalized with this virus had cardiovascular or cerebrovascular diseases. Systemic inflammatory response and immune system disorders during disease progression may be behind this association. In addition, the virus uses angiotensin‑converting enzyme (ACE) receptors, more precisely ACE2, to penetrate the cell; therefore, the use of ACE inhibitor drugs and angiotensin receptor blockers could cause an increase in these receptors, thus facilitating the entry of the virus into the cell. There is, however, no scientific evidence to support the interruption of these drugs. Since they are fundamental for certain chronic diseases, the risk and benefit of their withdrawal in this scenario should be carefully weighed. Finally, cardiologists and health professionals should be aware of the risks of infection and protect themselves as much as possible, sleeping properly and avoiding long working hours.
id SCI-1_a8682893fffe87e996a5c2953f96dd61
oai_identifier_str oai:ops.preprints.scielo.org:preprint/426
network_acronym_str SCI-1
network_name_str SciELO Preprints
repository_id_str
spelling COVID-19: Updated Data and its Relation to the Cardiovascular SystemCOVID-19: Updated Data and its Relation to the Cardiovascular SystemCOVID-19: Updated Data and its Relation to the Cardiovascular SystemCoronavirusCOVID 19Acute Respiratory Syndromecardiovascular Diseases/complicationsMyocarditisInfectious DiseasesRisk Factors/prevention and controlIn December 2019, a new human coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) or coronavirus disease 2019 (COVID‑19) by the World Health Organization, emerged in the city of Wuhan, China. Spreading globally, it is now considered pandemic, with approximately 3 million cases worldwide at the end of April. Its symptoms include fever, cough, and headache, but the main one is shortness of breath. In turn, it is believed that there is a relationship between COVID‑19 and damage to the heart muscle, and hypertensive and diabetic patients, for example, seem to have worse prognosis. Therefore, COVID‑19 may worsen in individuals with underlying adverse conditions, and a not negligible number of patients hospitalized with this virus had cardiovascular or cerebrovascular diseases. Systemic inflammatory response and immune system disorders during disease progression may be behind this association. In addition, the virus uses angiotensin‑converting enzyme (ACE) receptors, more precisely ACE2, to penetrate the cell; therefore, the use of ACE inhibitor drugs and angiotensin receptor blockers could cause an increase in these receptors, thus facilitating the entry of the virus into the cell. There is, however, no scientific evidence to support the interruption of these drugs. Since they are fundamental for certain chronic diseases, the risk and benefit of their withdrawal in this scenario should be carefully weighed. Finally, cardiologists and health professionals should be aware of the risks of infection and protect themselves as much as possible, sleeping properly and avoiding long working hours.SciELO PreprintsSciELO PreprintsSciELO Preprints2020-05-11info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/426enghttps://preprints.scielo.org/index.php/scielo/article/view/426/533Copyright (c) 2020 Filipe Ferrarihttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFerrari, Filipereponame:SciELO Preprintsinstname:SciELOinstacron:SCI2020-05-11T16:40:55Zoai:ops.preprints.scielo.org:preprint/426Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2020-05-11T16:40:55SciELO Preprints - SciELOfalse
dc.title.none.fl_str_mv COVID-19: Updated Data and its Relation to the Cardiovascular System
COVID-19: Updated Data and its Relation to the Cardiovascular System
COVID-19: Updated Data and its Relation to the Cardiovascular System
title COVID-19: Updated Data and its Relation to the Cardiovascular System
spellingShingle COVID-19: Updated Data and its Relation to the Cardiovascular System
Ferrari, Filipe
Coronavirus
COVID 19
Acute Respiratory Syndrome
cardiovascular Diseases/complications
Myocarditis
Infectious Diseases
Risk Factors/prevention and control
title_short COVID-19: Updated Data and its Relation to the Cardiovascular System
title_full COVID-19: Updated Data and its Relation to the Cardiovascular System
title_fullStr COVID-19: Updated Data and its Relation to the Cardiovascular System
title_full_unstemmed COVID-19: Updated Data and its Relation to the Cardiovascular System
title_sort COVID-19: Updated Data and its Relation to the Cardiovascular System
author Ferrari, Filipe
author_facet Ferrari, Filipe
author_role author
dc.contributor.author.fl_str_mv Ferrari, Filipe
dc.subject.por.fl_str_mv Coronavirus
COVID 19
Acute Respiratory Syndrome
cardiovascular Diseases/complications
Myocarditis
Infectious Diseases
Risk Factors/prevention and control
topic Coronavirus
COVID 19
Acute Respiratory Syndrome
cardiovascular Diseases/complications
Myocarditis
Infectious Diseases
Risk Factors/prevention and control
description In December 2019, a new human coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) or coronavirus disease 2019 (COVID‑19) by the World Health Organization, emerged in the city of Wuhan, China. Spreading globally, it is now considered pandemic, with approximately 3 million cases worldwide at the end of April. Its symptoms include fever, cough, and headache, but the main one is shortness of breath. In turn, it is believed that there is a relationship between COVID‑19 and damage to the heart muscle, and hypertensive and diabetic patients, for example, seem to have worse prognosis. Therefore, COVID‑19 may worsen in individuals with underlying adverse conditions, and a not negligible number of patients hospitalized with this virus had cardiovascular or cerebrovascular diseases. Systemic inflammatory response and immune system disorders during disease progression may be behind this association. In addition, the virus uses angiotensin‑converting enzyme (ACE) receptors, more precisely ACE2, to penetrate the cell; therefore, the use of ACE inhibitor drugs and angiotensin receptor blockers could cause an increase in these receptors, thus facilitating the entry of the virus into the cell. There is, however, no scientific evidence to support the interruption of these drugs. Since they are fundamental for certain chronic diseases, the risk and benefit of their withdrawal in this scenario should be carefully weighed. Finally, cardiologists and health professionals should be aware of the risks of infection and protect themselves as much as possible, sleeping properly and avoiding long working hours.
publishDate 2020
dc.date.none.fl_str_mv 2020-05-11
dc.type.driver.fl_str_mv info:eu-repo/semantics/preprint
info:eu-repo/semantics/publishedVersion
format preprint
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://preprints.scielo.org/index.php/scielo/preprint/view/426
url https://preprints.scielo.org/index.php/scielo/preprint/view/426
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://preprints.scielo.org/index.php/scielo/article/view/426/533
dc.rights.driver.fl_str_mv Copyright (c) 2020 Filipe Ferrari
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Filipe Ferrari
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
publisher.none.fl_str_mv SciELO Preprints
SciELO Preprints
SciELO Preprints
dc.source.none.fl_str_mv reponame:SciELO Preprints
instname:SciELO
instacron:SCI
instname_str SciELO
instacron_str SCI
institution SCI
reponame_str SciELO Preprints
collection SciELO Preprints
repository.name.fl_str_mv SciELO Preprints - SciELO
repository.mail.fl_str_mv scielo.submission@scielo.org
_version_ 1797047817342025728